Evidence your R&D agents can cite, from target to label.
Full-text papers, clinical trials, chemistry, structures and patents in one API, for teams building AI across discovery and development.
Pipeline
Across the pipeline.
Each stage asks different questions of different sources. Pick a stage.
Questions teams ask at this stage
- What human genetic evidence links TYK2 to autoimmune disease?
- Which cell types express the target, and what happens on knockout?
- Is there a tractable binding site, and what chemical matter already exists?
- Who else is in the clinic on this target, and at what phase?
PCSK9
One target, followed through the pipeline.
PCSK9, from a genetic observation to an approved class, as a Valyu search would find it.
Loss-of-function carriers had lower LDL and markedly lower coronary risk.
A neutralising antibody reduced serum cholesterol in mice and non-human primates.
Evolocumab reduced major cardiovascular events on top of statins.
Approved in the US in 2015 for LDL lowering; cardiovascular risk reduction added in 2017.
An siRNA, inclisiran, halved LDL with twice-yearly dosing.
For investors & BD
Diligence the science, not the deck.
Test an asset’s mechanism, trial record and patent position against the full literature before the term sheet.
- Does the human genetics support the mechanism the company claims?
- How did every prior trial on this target read out?
- Who holds the composition-of-matter patents, and when do they expire?
- Which competitors are ahead, and by how many phases?
Clinical software
Building clinical or health software?
The same trial, label and literature data grounds clinical decision support, prior authorisation and medical information tools. Every conclusion carries a citation a clinician can open.
| Evidence | Finding | Source |
|---|---|---|
| Recommendation | Osimertinib | FLAURA, NEJM |
| Label | Approved first line, exon 19 and 21 mutations | DailyMed |
| Trial evidence | Median PFS 18.9 vs 10.2 months | ClinicalTrials.gov |
Benchmarks
Proof on medical and biology questions.
MedAgent
482 hard medical questions, including clinical trials and drug labels, curated from 10 medical benchmarks.
FAQ
Questions from R&D teams.
Can we separate preprints from peer-reviewed papers?
How current are trial records?
Which patent offices do you cover?
Enterprise on Valyu.
Private indexes on your firm's internal data, enterprise controls, and engineers who ship with you.
Talk to our team
SOC 2, Zero Data Retention, SSO with SAML or OIDC, scoped tenant isolation. US, EU, and UK deployment options, or dedicated in your VPC.
State-of-the-art retrieval on internal data: lab notebooks, internal reports, trial data, research archives. Agents run on your own research and every Valyu source, in one call.
When the API needs to go further, our engineers ship with you. Custom DeepResearch agents and vertical indexes tuned to your field.
See it on your own programme
Send us a target. We’ll send back the dossier.
Genetics, tractability, clinical precedent and competition, cited line by line, before your first call with us.